TY - JOUR
T1 - The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: the role of denosumab
AU - Capozzi, Anna
AU - Lello, Stefano
AU - Pontecorvi, Alfredo
PY - 2014
Y1 - 2014
N2 - There is great interest in new treatments of osteoporosis owing to general ageing of population and increased risk for fragility fractures in the elderly. Current therapies show a good efficacy in improving bone quality and bone density, but, in spite of a certain reduction in fracture rate, according to each treatment, the problem of osteoporotic fractures is yet far from to be solved. Moreover, some treatments may produce different side effects. Denosumab (Dmab), a receptor activator of nuclear factor kappa-B ligand (RANKL)-inhibitor, is an agent recently introduced in clinical practice for treatment of osteoporosis of postmenopausal women. Dmab has improved bone mineral density and prevented new vertebral and non-vertebral fractures with a similar efficacy in comparison with alendronate. Many clinical studies showed Dmab produces also significant improvement versus placebo in bone quality as indicated by decreasing markers of bone turnover. Patients using Dmab reported less risk of AFF (Atypical Femoral Fractures) and ONJ (Osteonecrosis of the Jaw) with an increased number of cellulitis. Here, we review articles using Dmab for female post-menopausal osteoporosis.
AB - There is great interest in new treatments of osteoporosis owing to general ageing of population and increased risk for fragility fractures in the elderly. Current therapies show a good efficacy in improving bone quality and bone density, but, in spite of a certain reduction in fracture rate, according to each treatment, the problem of osteoporotic fractures is yet far from to be solved. Moreover, some treatments may produce different side effects. Denosumab (Dmab), a receptor activator of nuclear factor kappa-B ligand (RANKL)-inhibitor, is an agent recently introduced in clinical practice for treatment of osteoporosis of postmenopausal women. Dmab has improved bone mineral density and prevented new vertebral and non-vertebral fractures with a similar efficacy in comparison with alendronate. Many clinical studies showed Dmab produces also significant improvement versus placebo in bone quality as indicated by decreasing markers of bone turnover. Patients using Dmab reported less risk of AFF (Atypical Femoral Fractures) and ONJ (Osteonecrosis of the Jaw) with an increased number of cellulitis. Here, we review articles using Dmab for female post-menopausal osteoporosis.
KW - Antibodies, Monoclonal, Humanized
KW - Bone Density Conservation Agents
KW - Cellulitis
KW - Denosumab
KW - Female
KW - Humans
KW - Molecular Targeted Therapy
KW - Osteoclasts
KW - Osteoporosis, Postmenopausal
KW - Osteoporotic Fractures
KW - RANK Ligand
KW - RANKL
KW - osteoporosis
KW - osteoporotic fracture
KW - Antibodies, Monoclonal, Humanized
KW - Bone Density Conservation Agents
KW - Cellulitis
KW - Denosumab
KW - Female
KW - Humans
KW - Molecular Targeted Therapy
KW - Osteoclasts
KW - Osteoporosis, Postmenopausal
KW - Osteoporotic Fractures
KW - RANK Ligand
KW - RANKL
KW - osteoporosis
KW - osteoporotic fracture
UR - http://hdl.handle.net/10807/64343
U2 - 10.3109/09513590.2014.892067
DO - 10.3109/09513590.2014.892067
M3 - Article
SN - 0951-3590
VL - 30
SP - 403
EP - 408
JO - Gynecological Endocrinology
JF - Gynecological Endocrinology
ER -